Stevanato Group unveils two new products at Pharmapack: Nexa FlexTM polymer syringes and its Special Thin-Wall needle
KEY LEARNING OBJECTIVES
Stevanato Group latest developments are aimed at supporting the growth in the biologic market.
Nexa FlexTM polymer syringe, is Stevanato Group latest addition to its existing portfolio, now offering both COP and COC pre-fillable syringes (PFS) to providing its customers with the broadest choice for PFS.
Stevanato Group is an integrated solution provider offering solutions for the entire drug life cycle from analytical services to drug delivery systems.
Proposal for the Public Procurement Act, adoption of a new pharmaceutical legislation, and revision of pharmacovigilance practices should improve patient access to safe and innovative medicines in Europe.
This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.